SIMILAR PATTERNS OF AMINO ACIDS FOR 3QXT_A_MTXA2000_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1g6v	ANTIBODY HEAVY CHAIN (Camelus dromedarius)	PF07686 (V-set)	5	VAL K 802 ALA K 824 MET K 834 ASN K 875 VAL K 877	None	0.84A	3qxtA-1g6vK: 20.4	3qxtA-1g6vK: 70.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1i3u	ANTIBODY VHH LAMA DOMAIN (Lama glama)	PF07686 (V-set)	5	ALA A 24 ARG A 77 ASN A 82 VAL A 84 ALA A 103	None	0.80A	3qxtA-1i3uA: 20.9	3qxtA-1i3uA: 60.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1ind	IGG1-LAMBDA CHA255 FAB (HEAVY CHAIN) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 72 ASN H 77	None	0.93A	3qxtA-1indH: 19.6	3qxtA-1indH: 36.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1pz5	HEAVY CHAIN OF FAB (SYA/J6) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 71 VAL B 78	None	0.83A	3qxtA-1pz5B: 20.2	3qxtA-1pz5B: 52.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2x6m	HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY (Camelus dromedarius)	PF07686 (V-set)	5	ALA A 24 MET A 34 ASN A 78 VAL A 80 ALA A 99	None	0.65A	3qxtA-2x6mA: 21.5	3qxtA-2x6mA: 69.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 71 ASN B 76 ALA B 94	None	0.90A	3qxtA-3g9aB: 20.0	3qxtA-3g9aB: 66.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 94	None	0.77A	3qxtA-3g9aB: 20.0	3qxtA-3g9aB: 66.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k80	ANTIBODY (Lama glama)	PF07686 (V-set)	5	ALA A 24 MET A 34 ARG A 72 ASN A 77 VAL A 79	None	0.93A	3qxtA-3k80A: 22.2	3qxtA-3k80A: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k80	ANTIBODY (Lama glama)	PF07686 (V-set)	5	VAL A 2 ALA A 24 ARG A 72 ASN A 77 VAL A 79	None	1.06A	3qxtA-3k80A: 22.2	3qxtA-3k80A: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	6	VAL A 4 ALA A 26 MET A 36 ARG A 74 VAL A 81 ALA A 100	None	0.81A	3qxtA-3qxuA: 25.6	3qxtA-3qxuA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	6	VAL A 4 ALA A 26 SER A 30 MET A 36 VAL A 81 ALA A 100	None	0.93A	3qxtA-3qxuA: 25.6	3qxtA-3qxuA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	6	VAL A 4 ALA A 26 SER A 30 SER A 31 MET A 36 ALA A 100	None	1.01A	3qxtA-3qxuA: 25.6	3qxtA-3qxuA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	6	VAL A 4 ALA A 26 SER A 31 MET A 36 ARG A 74 ALA A 100	None	0.70A	3qxtA-3qxuA: 25.6	3qxtA-3qxuA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qyc	VH DOMAIN OF IGG MOLECULE (Homo sapiens)	PF07686 (V-set)	5	VAL A 4 ALA A 26 MET A 36 ARG A 74 VAL A 81	None	0.69A	3qxtA-3qycA: 19.8	3qxtA-3qycA: 62.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3r0m	LLAMA VHH A12 (Lama glama)	PF07686 (V-set)	5	ALA A 24 SER A 29 MET A 34 VAL A 78 ALA A 94	None SO4 A 131 (-2.7A) None None None	0.83A	3qxtA-3r0mA: 21.2	3qxtA-3r0mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	ALA A 26 MET A 36 ARG A 73 ASN A 78 VAL A 80 ALA A 99	None	0.79A	3qxtA-3stbA: 22.2	3qxtA-3stbA: 71.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	5	VAL A 4 ALA A 26 ARG A 73 ASN A 78 VAL A 80	None	1.00A	3qxtA-3stbA: 22.2	3qxtA-3stbA: 71.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tpk	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN KW1 (Camelidae)	PF07686 (V-set)	5	VAL A 2 ALA A 24 ASN A 77 VAL A 79 ALA A 98	None BEN A 133 (-3.6A) BEN A 133 (-3.3A) BEN A 133 (-4.6A) BEN A 133 ( 4.2A)	0.76A	3qxtA-3tpkA: 20.9	3qxtA-3tpkA: 64.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4b41	ANTIBODY G7 (Lama glama)	PF07686 (V-set)	5	VAL A 2 ALA A 24 MET A 34 VAL A 78 ALA A 97	None	0.92A	3qxtA-4b41A: 19.0	3qxtA-4b41A: 72.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	ALA A 24 SER A 30 MET A 34 ARG A 72 VAL A 79 ALA A 98	None	1.47A	3qxtA-4dkaA: 22.6	3qxtA-4dkaA: 74.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	VAL A 2 ALA A 24 MET A 34 ARG A 72 ASN A 77 ALA A 98	None	0.95A	3qxtA-4dkaA: 22.6	3qxtA-4dkaA: 74.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	VAL A 2 ALA A 24 MET A 34 ARG A 72 VAL A 79 ALA A 98	None	0.83A	3qxtA-4dkaA: 22.6	3qxtA-4dkaA: 74.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4eig	CA1698 CAMEL ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 97	None	0.68A	3qxtA-4eigB: 20.5	3qxtA-4eigB: 67.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f58	HEAVY CHAIN OF FAB OF A NEUTRALIZING ANTIBODY L3 (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	ALA H 24 MET H 34 ARG H 71 ASN H 76 VAL H 78	None	1.04A	3qxtA-4f58H: 20.3	3qxtA-4f58H: 61.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f58	HEAVY CHAIN OF FAB OF A NEUTRALIZING ANTIBODY L3 (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78	None	1.00A	3qxtA-4f58H: 20.3	3qxtA-4f58H: 61.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hem	ANTI-BASEPLATE TP901-1 LLAMA VHH 02 (Lama glama)	PF07686 (V-set)	5	ALA E 24 MET E 34 ARG E 72 VAL E 79 ALA E 98	None	0.57A	3qxtA-4hemE: 23.2	3qxtA-4hemE: 74.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4kfz	ANTI-LMO2 VH (Homo sapiens)	PF07686 (V-set)	5	ALA C 24 SER C 28 MET C 34 ARG C 72 ASN C 77	None	0.88A	3qxtA-4kfzC: 20.4	3qxtA-4kfzC: 62.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4kml	NANOBODY (Lama glama)	PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 72 ASN B 77	None	0.91A	3qxtA-4kmlB: 23.0	3qxtA-4kmlB: 67.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 72 ASN B 77 VAL B 79 ALA B 98	None	0.82A	3qxtA-4krmB: 23.3	3qxtA-4krmB: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	5	SER B 29 MET B 34 ARG B 72 VAL B 79 ALA B 98	None	0.47A	3qxtA-4krmB: 23.3	3qxtA-4krmB: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4kvn	HUMAN IGG HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	6	VAL H 2 ALA H 24 SER H 30 ARG H 72 ASN H 77 VAL H 79	None	0.85A	3qxtA-4kvnH: 19.6	3qxtA-4kvnH: 42.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lhj	CAMELID ANTIBODY (Vicugna pacos)	PF07686 (V-set) PF07705 (CARDB)	5	SER B 27 ARG B 102 MET B 34 VAL B 78 ALA B 97	None	0.97A	3qxtA-4lhjB: 18.1	3qxtA-4lhjB: 68.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lhq	CAMELID NANOBODY (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 SER B 28 MET B 34 ARG B 72 VAL B 79	None	0.91A	3qxtA-4lhqB: 21.6	3qxtA-4lhqB: 64.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc1	A20.1 VHH (Lama glama)	PF07686 (V-set)	7	VAL C 9 ALA C 31 MET C 41 ARG C 79 ASN C 84 VAL C 86 ALA C 105	None	1.01A	3qxtA-4nc1C: 21.9	3qxtA-4nc1C: 70.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 71 ASN B 76 ALA B 97	None	0.95A	3qxtA-4nc2B: 23.1	3qxtA-4nc2B: 71.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4orz	SINGLE DOMAIN ANTIBODY SDAB19 (Lama glama)	PF07686 (V-set)	5	ALA C 26 MET C 36 ARG C 73 ASN C 78 VAL C 80	None	0.96A	3qxtA-4orzC: 20.7	3qxtA-4orzC: 65.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	5	MET G 34 ARG G 71 ASN G 76 VAL G 78 ALA G 97	None	0.76A	3qxtA-4p2cG: 19.2	3qxtA-4p2cG: 71.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	5	VAL G 2 MET G 34 ARG G 71 VAL G 78 ALA G 97	None	0.68A	3qxtA-4p2cG: 19.2	3qxtA-4p2cG: 71.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4py8	ANTIBODY 3.1 HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL I 2 ALA I 24 ARG I 72 ASN I 77 VAL I 79	None	0.72A	3qxtA-4py8I: 21.0	3qxtA-4py8I: 65.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qo1	NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53 (Lama glama)	PF07686 (V-set)	6	ALA A 25 MET A 35 ARG A 73 ASN A 78 VAL A 80 ALA A 99	None	0.73A	3qxtA-4qo1A: 20.8	3qxtA-4qo1A: 63.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4s10	GELSOLIN NANOBODY (Lama glama)	PF07686 (V-set)	5	VAL A 2 ALA A 24 ASN A 77 VAL A 79 ALA A 98	None	0.70A	3qxtA-4s10A: 22.1	3qxtA-4s10A: 71.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4s10	GELSOLIN NANOBODY (Lama glama)	PF07686 (V-set)	5	VAL A 2 MET A 34 ASN A 77 VAL A 79 ALA A 98	None	1.03A	3qxtA-4s10A: 22.1	3qxtA-4s10A: 71.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4tvs	VHH DOMAIN BS-1 (Vicugna pacos)	PF05609 (LAP1C)	5	ALA a 25 ARG a 73 ASN a 78 VAL a 80 ALA a 99	None	0.76A	3qxtA-4tvsa: 22.8	3qxtA-4tvsa: 73.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ASN B 77 VAL B 79 ALA B 98	None	0.93A	3qxtA-4w6yB: 21.5	3qxtA-4w6yB: 70.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4x7f	NANO-25 NANOBODY (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 ALA C 24 MET C 34 ASN C 76 VAL C 78	None	0.93A	3qxtA-4x7fC: 18.9	3qxtA-4x7fC: 63.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xt1	NANOBODY 7 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 ALA C 24 MET C 34 VAL C 78 ALA C 97	None	0.91A	3qxtA-4xt1C: 19.3	3qxtA-4xt1C: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydk	HEAVY CHAIN OF ANTIBODY C38-VRC16.01 (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78	None	1.03A	3qxtA-4ydkH: 20.0	3qxtA-4ydkH: 35.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yga	VHH-1B7 (Vicugna pacos)	PF07686 (V-set)	5	ALA B 25 ARG B 73 ASN B 78 VAL B 80 ALA B 99	None	0.66A	3qxtA-4ygaB: 20.4	3qxtA-4ygaB: 61.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4zfo	J22.9-XI FAB, HEAVY CHAIN (Mus musculus)	no annotation	5	VAL H 2 ALA H 24 MET H 34 ARG H 72 ASN H 77	None	0.98A	3qxtA-4zfoH: 18.7	3qxtA-4zfoH: 37.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a2k	IG LAMBDA-1 CHAIN V REGION S43 (Mus musculus)	PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78	None	0.88A	3qxtA-5a2kH: 19.9	3qxtA-5a2kH: 29.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	5	ALA H 24 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.64A	3qxtA-5aumH: 19.7	3qxtA-5aumH: 38.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	5	VAL H 2 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.54A	3qxtA-5aumH: 19.7	3qxtA-5aumH: 38.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b6f	ANTI-LEUKOTRIENE C4 MONOCLONAL ANTIBODY IMMUNOGLOBULIN GAMMA1 HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	ALA B 43 MET B 53 ARG B 93 ASN B 98 VAL B 100	None	0.57A	3qxtA-5b6fB: 19.3	3qxtA-5b6fB: 36.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e1h	F8(JOB10) VHH ANTIBODY (Vicugna pacos)	PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 72 VAL B 79	None	0.94A	3qxtA-5e1hB: 20.6	3qxtA-5e1hB: 69.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	5	ALA A 26 ARG A 73 ASN A 78 VAL A 80 ALA A 99	None	0.95A	3qxtA-5e7fA: 18.9	3qxtA-5e7fA: 67.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	5	MET A 36 ARG A 73 ASN A 78 VAL A 80 ALA A 99	None	0.63A	3qxtA-5e7fA: 18.9	3qxtA-5e7fA: 67.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	5	VAL A 4 ALA A 26 ARG A 73 VAL A 80 ALA A 99	None	0.98A	3qxtA-5e7fA: 18.9	3qxtA-5e7fA: 67.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	5	VAL A 4 MET A 36 ARG A 73 VAL A 80 ALA A 99	None	0.76A	3qxtA-5e7fA: 18.9	3qxtA-5e7fA: 67.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1k	NANOBODY MU1053 (Lama glama)	PF07686 (V-set)	5	MET C 34 ARG C 72 ASN C 77 VAL C 79 ALA C 98	None	0.32A	3qxtA-5f1kC: 22.3	3qxtA-5f1kC: 68.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	5	ALA A 24 MET A 34 ARG A 71 ASN A 76 ALA A 94	None	0.92A	3qxtA-5fwoA: 21.7	3qxtA-5fwoA: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL A 2 ALA A 24 MET A 34 ARG A 71 VAL A 78 ALA A 94	None	0.92A	3qxtA-5fwoA: 21.7	3qxtA-5fwoA: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gxb	NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ASN B 77 VAL B 79 ALA B 98	None	0.92A	3qxtA-5gxbB: 21.0	3qxtA-5gxbB: 69.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	5	VAL B 2 ALA B 24 ARG B 70 VAL B 77 ALA B 96	None	0.88A	3qxtA-5hvfB: 18.7	3qxtA-5hvfB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 VAL B 77 ALA B 96	None	1.03A	3qxtA-5hvfB: 18.7	3qxtA-5hvfB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	6	ALA B 23 MET B 33 ARG B 71 ASN B 76 VAL B 78 ALA B 97	None	0.84A	3qxtA-5imlB: 23.7	3qxtA-5imlB: 76.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	7	VAL C 3 ALA C 25 MET C 35 ARG C 72 ASN C 77 VAL C 79 ALA C 98	None	0.96A	3qxtA-5j1sC: 19.6	3qxtA-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j56	VHH SINGLE CHAIN ANTIBODY V1C7 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 ARG B 76 ASN B 81 VAL B 83 ALA B 102	None	0.90A	3qxtA-5j56B: 21.3	3qxtA-5j56B: 67.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ja8	NANOBODY 2 (Lama glama)	PF07686 (V-set)	5	ALA B 25 ARG B 73 ASN B 78 VAL B 80 ALA B 99	None	0.56A	3qxtA-5ja8B: 20.6	3qxtA-5ja8B: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ja9	NANOBODY 6 (Lama glama)	PF07686 (V-set)	5	ALA A 25 MET A 35 ARG A 73 ASN A 78 ALA A 99	None	1.01A	3qxtA-5ja9A: 20.4	3qxtA-5ja9A: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jqh	NANOBODY60, NB60 (Lama glama)	no annotation	5	VAL D 2 MET D 34 ARG D 71 VAL D 78 ALA D 97	None	0.97A	3qxtA-5jqhD: 19.5	3qxtA-5jqhD: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5kel	C2G4 VARIABLE FAB DOMAIN HEAVY CHAIN (Homo sapiens)	PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78	None	1.01A	3qxtA-5kelH: 17.3	3qxtA-5kelH: 51.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhq	CAMELID-DERIVED ANTIBODY FRAGMENT NB7 (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 ARG B 72 ASN B 77 VAL B 79 ALA B 98	None	0.54A	3qxtA-5lhqB: 21.8	3qxtA-5lhqB: 65.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhq	CAMELID-DERIVED ANTIBODY FRAGMENT NB7 (Vicugna pacos)	PF07686 (V-set)	5	VAL B 2 ARG B 72 ASN B 77 VAL B 79 ALA B 98	None	0.66A	3qxtA-5lhqB: 21.8	3qxtA-5lhqB: 65.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhr	CAMELID-DERIVED ANTIBODY FRAGMENT NB22 (Vicugna pacos)	PF07686 (V-set)	5	MET B 34 ARG B 72 ASN B 77 VAL B 79 ALA B 98	None	0.87A	3qxtA-5lhrB: 19.9	3qxtA-5lhrB: 76.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	ALA A 24 MET A 34 ARG A 71 ASN A 76 VAL A 78 ALA A 94	None	0.95A	3qxtA-5lmjA: 20.3	3qxtA-5lmjA: 74.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL A 2 ALA A 24 ARG A 71 ASN A 76 VAL A 78 ALA A 94	None	0.89A	3qxtA-5lmjA: 20.3	3qxtA-5lmjA: 74.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	6	ALA C 27 MET C 37 ARG C 75 ASN C 80 VAL C 82 ALA C 101	None	0.57A	3qxtA-5lwfC: 21.3	3qxtA-5lwfC: 69.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	6	VAL C 5 MET C 37 ARG C 75 ASN C 80 VAL C 82 ALA C 101	None	0.71A	3qxtA-5lwfC: 21.3	3qxtA-5lwfC: 69.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5mwn	LLAMA NANOBODY RAISED AGAINST TSSK, NBK27 (Lama glama)	PF07686 (V-set)	5	VAL N 2 ALA N 24 ARG N 71 VAL N 78 ALA N 97	None	0.91A	3qxtA-5mwnN: 18.4	3qxtA-5mwnN: 66.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5mwn	LLAMA NANOBODY RAISED AGAINST TSSK, NBK27 (Lama glama)	PF07686 (V-set)	5	VAL N 2 ALA N 24 MET N 34 VAL N 78 ALA N 97	None	0.94A	3qxtA-5mwnN: 18.4	3qxtA-5mwnN: 66.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o05	NANOBODY (VHH) NANO-42 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 ALA C 24 SER C 29 ASN C 76 VAL C 78	None	0.82A	3qxtA-5o05C: 17.3	3qxtA-5o05C: 66.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o8f	NANOBODY NB25 (Lama glama)	no annotation	5	MET L 34 ARG L 72 ASN L 77 VAL L 79 ALA L 98	None	0.91A	3qxtA-5o8fL: 21.5	3qxtA-5o8fL: 69.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ovw	NANOBODY (Lama glama)	no annotation	5	ALA G 46 ARG G 94 ASN G 99 VAL G 101 ALA G 120	None	0.48A	3qxtA-5ovwG: 21.6	3qxtA-5ovwG: 60.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	5	ALA p 24 MET p 34 ARG p 72 ASN p 77 ALA p 98	None	1.01A	3qxtA-5uk4p: 21.7	3qxtA-5uk4p: 70.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	5	MET p 34 ARG p 72 ASN p 77 VAL p 79 ALA p 98	None	0.75A	3qxtA-5uk4p: 21.7	3qxtA-5uk4p: 70.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	5	VAL p 2 MET p 34 ARG p 72 VAL p 79 ALA p 98	None	0.80A	3qxtA-5uk4p: 21.7	3qxtA-5uk4p: 70.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ukb	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	6	ALA d 24 ARG d 30 ARG d 72 ASN d 77 VAL d 79 ALA d 98	None	1.05A	3qxtA-5ukbd: 22.4	3qxtA-5ukbd: 72.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vaq	NB914 (Lama glama)	no annotation	6	ALA B 24 SER B 30 ARG B 72 ASN B 77 VAL B 79 ALA B 98	None	1.05A	3qxtA-5vaqB: 22.9	3qxtA-5vaqB: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vgj	VRC38.01 FAB HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	6	VAL H 2 ALA H 24 MET H 34 ARG H 71 ASN H 76 VAL H 78	None	0.64A	3qxtA-5vgjH: 19.3	3qxtA-5vgjH: 37.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vnw	NB.B201 (synthetic construct)	no annotation	5	VAL C 2 ALA C 24 MET C 34 ASN C 76 VAL C 78	None	0.94A	3qxtA-5vnwC: 21.0	3qxtA-5vnwC: 75.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	5	MET B 34 ARG B 72 ASN B 77 VAL B 79 ALA B 98	None	0.76A	3qxtA-5vxjB: 19.3	3qxtA-5vxjB: 63.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	5	VAL B 2 MET B 34 ARG B 72 VAL B 79 ALA B 98	None	0.71A	3qxtA-5vxjB: 19.3	3qxtA-5vxjB: 63.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxk	SINGLE-DOMAIN ANTIBODY JMK-H2 (Vicugna pacos)	no annotation	5	ALA B 24 ARG B 72 ASN B 77 VAL B 79 ALA B 98	None	0.45A	3qxtA-5vxkB: 21.5	3qxtA-5vxkB: 67.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	5	ALA B 24 MET B 34 ARG B 73 VAL B 80 ALA B 99	None	0.68A	3qxtA-5vxlB: 20.4	3qxtA-5vxlB: 64.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wb1	ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN (Human betaherpesvirus 5; Lama glama)	no annotation	5	VAL A1002 ALA A1024 MET A1034 VAL A1078 ALA A1097	None	0.96A	3qxtA-5wb1A: 18.3	3qxtA-5wb1A: 14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	VAL A 2 ALA A 24 MET A 34 ASN A 77 VAL A 79 ALA A 98	None	0.75A	3qxtA-6dbeA: 20.7	3qxtA-6dbeA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	ALA C 24 MET C 34 ARG C 72 VAL C 79 ALA C 98	None	0.65A	3qxtA-6ehgC: 22.2	3qxtA-6ehgC: 74.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	5	VAL C 2 ALA C 24 MET C 34 ARG C 72 VAL C 79	None	0.89A	3qxtA-6ehgC: 22.2	3qxtA-6ehgC: 74.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6gzp	NANOBODY (Lama glama)	no annotation	5	ALA A 24 MET A 34 ARG A 71 ASN A 76 ALA A 94	None	0.88A	3qxtA-6gzpA: 21.8	3qxtA-6gzpA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6gzp	NANOBODY (Lama glama)	no annotation	5	VAL A 2 ALA A 24 MET A 34 ARG A 71 ALA A 94	None	0.83A	3qxtA-6gzpA: 21.8	3qxtA-6gzpA: undetectable

[["3QXT_A_MTXA2000_1","1g6v","Camelus dromedarius","ANTIBODY HEAVY CHAIN","PF07686(V-set)",5,"VAL K 802;ALA K 824;MET K 834;ASN K 875;VAL K 877","None","0.84A","3qxtA-1g6vK:20.4","3qxtA-1g6vK:70.31"],["3QXT_A_MTXA2000_1","1i3u","Lama glama","ANTIBODY VHH LAMA DOMAIN","PF07686(V-set)",5,"ALA A  24;ARG A  77;ASN A  82;VAL A  84;ALA A 103","None","0.80A","3qxtA-1i3uA:20.9","3qxtA-1i3uA:60.58"],["3QXT_A_MTXA2000_1","1ind","Mus musculus","IGG1-LAMBDA CHA255 FAB (HEAVY CHAIN)","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  72;ASN H  77","None","0.93A","3qxtA-1indH:19.6","3qxtA-1indH:36.70"],["3QXT_A_MTXA2000_1","1pz5","Mus musculus","HEAVY CHAIN OF FAB (SYA\/J6)","PF07654(C1-set);PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  71;VAL B  78","None","0.83A","3qxtA-1pz5B:20.2","3qxtA-1pz5B:52.27"],["3QXT_A_MTXA2000_1","2x6m","Camelus dromedarius","HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY","PF07686(V-set)",5,"ALA A  24;MET A  34;ASN A  78;VAL A  80;ALA A  99","None","0.65A","3qxtA-2x6mA:21.5","3qxtA-2x6mA:69.77"],["3QXT_A_MTXA2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  71;ASN B  76;ALA B  94","None","0.90A","3qxtA-3g9aB:20.0","3qxtA-3g9aB:66.42"],["3QXT_A_MTXA2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  94","None","0.77A","3qxtA-3g9aB:20.0","3qxtA-3g9aB:66.42"],["3QXT_A_MTXA2000_1","3k80","Lama glama","ANTIBODY","PF07686(V-set)",5,"ALA A  24;MET A  34;ARG A  72;ASN A  77;VAL A  79","None","0.93A","3qxtA-3k80A:22.2","3qxtA-3k80A:70.16"],["3QXT_A_MTXA2000_1","3k80","Lama glama","ANTIBODY","PF07686(V-set)",5,"VAL A   2;ALA A  24;ARG A  72;ASN A  77;VAL A  79","None","1.06A","3qxtA-3k80A:22.2","3qxtA-3k80A:70.16"],["3QXT_A_MTXA2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",6,"VAL A   4;ALA A  26;MET A  36;ARG A  74;VAL A  81;ALA A 100","None","0.81A","3qxtA-3qxuA:25.6","3qxtA-3qxuA:100.00"],["3QXT_A_MTXA2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",6,"VAL A   4;ALA A  26;SER A  30;MET A  36;VAL A  81;ALA A 100","None","0.93A","3qxtA-3qxuA:25.6","3qxtA-3qxuA:100.00"],["3QXT_A_MTXA2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",6,"VAL A   4;ALA A  26;SER A  30;SER A  31;MET A  36;ALA A 100","None","1.01A","3qxtA-3qxuA:25.6","3qxtA-3qxuA:100.00"],["3QXT_A_MTXA2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",6,"VAL A   4;ALA A  26;SER A  31;MET A  36;ARG A  74;ALA A 100","None","0.70A","3qxtA-3qxuA:25.6","3qxtA-3qxuA:100.00"],["3QXT_A_MTXA2000_1","3qyc","Homo sapiens","VH DOMAIN OF IGG MOLECULE","PF07686(V-set)",5,"VAL A   4;ALA A  26;MET A  36;ARG A  74;VAL A  81","None","0.69A","3qxtA-3qycA:19.8","3qxtA-3qycA:62.99"],["3QXT_A_MTXA2000_1","3r0m","Lama glama","LLAMA VHH A12","PF07686(V-set)",5,"ALA A  24;SER A  29;MET A  34;VAL A  78;ALA A  94","None;SO4 A 131 (-2.7A);None;None;None","0.83A","3qxtA-3r0mA:21.2","3qxtA-3r0mA:70.54"],["3QXT_A_MTXA2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"ALA A  26;MET A  36;ARG A  73;ASN A  78;VAL A  80;ALA A  99","None","0.79A","3qxtA-3stbA:22.2","3qxtA-3stbA:71.54"],["3QXT_A_MTXA2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",5,"VAL A   4;ALA A  26;ARG A  73;ASN A  78;VAL A  80","None","1.00A","3qxtA-3stbA:22.2","3qxtA-3stbA:71.54"],["3QXT_A_MTXA2000_1","3tpk","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN KW1","PF07686(V-set)",5,"VAL A   2;ALA A  24;ASN A  77;VAL A  79;ALA A  98","None;BEN A 133 (-3.6A);BEN A 133 (-3.3A);BEN A 133 (-4.6A);BEN A 133 ( 4.2A)","0.76A","3qxtA-3tpkA:20.9","3qxtA-3tpkA:64.84"],["3QXT_A_MTXA2000_1","4b41","Lama glama","ANTIBODY G7","PF07686(V-set)",5,"VAL A   2;ALA A  24;MET A  34;VAL A  78;ALA A  97","None","0.92A","3qxtA-4b41A:19.0","3qxtA-4b41A:72.44"],["3QXT_A_MTXA2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"ALA A  24;SER A  30;MET A  34;ARG A  72;VAL A  79;ALA A  98","None","1.47A","3qxtA-4dkaA:22.6","3qxtA-4dkaA:74.02"],["3QXT_A_MTXA2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"VAL A   2;ALA A  24;MET A  34;ARG A  72;ASN A  77;ALA A  98","None","0.95A","3qxtA-4dkaA:22.6","3qxtA-4dkaA:74.02"],["3QXT_A_MTXA2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"VAL A   2;ALA A  24;MET A  34;ARG A  72;VAL A  79;ALA A  98","None","0.83A","3qxtA-4dkaA:22.6","3qxtA-4dkaA:74.02"],["3QXT_A_MTXA2000_1","4eig","Lama glama","CA1698 CAMEL ANTIBODY FRAGMENT","PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  97","None","0.68A","3qxtA-4eigB:20.5","3qxtA-4eigB:67.74"],["3QXT_A_MTXA2000_1","4f58","Homo sapiens","HEAVY CHAIN OF FAB OF A NEUTRALIZING ANTIBODY L3","PF07654(C1-set);PF07686(V-set)",5,"ALA H  24;MET H  34;ARG H  71;ASN H  76;VAL H  78","None","1.04A","3qxtA-4f58H:20.3","3qxtA-4f58H:61.42"],["3QXT_A_MTXA2000_1","4f58","Homo sapiens","HEAVY CHAIN OF FAB OF A NEUTRALIZING ANTIBODY L3","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78","None","1.00A","3qxtA-4f58H:20.3","3qxtA-4f58H:61.42"],["3QXT_A_MTXA2000_1","4hem","Lama glama","ANTI-BASEPLATE TP901-1 LLAMA VHH 02","PF07686(V-set)",5,"ALA E  24;MET E  34;ARG E  72;VAL E  79;ALA E  98","None","0.57A","3qxtA-4hemE:23.2","3qxtA-4hemE:74.19"],["3QXT_A_MTXA2000_1","4kfz","Homo sapiens","ANTI-LMO2 VH","PF07686(V-set)",5,"ALA C  24;SER C  28;MET C  34;ARG C  72;ASN C  77","None","0.88A","3qxtA-4kfzC:20.4","3qxtA-4kfzC:62.88"],["3QXT_A_MTXA2000_1","4kml","Lama glama","NANOBODY","PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  72;ASN B  77","None","0.91A","3qxtA-4kmlB:23.0","3qxtA-4kmlB:67.46"],["3QXT_A_MTXA2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  72;ASN B  77;VAL B  79;ALA B  98","None","0.82A","3qxtA-4krmB:23.3","3qxtA-4krmB:70.97"],["3QXT_A_MTXA2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",5,"SER B  29;MET B  34;ARG B  72;VAL B  79;ALA B  98","None","0.47A","3qxtA-4krmB:23.3","3qxtA-4krmB:70.97"],["3QXT_A_MTXA2000_1","4kvn","Homo sapiens","HUMAN IGG HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",6,"VAL H   2;ALA H  24;SER H  30;ARG H  72;ASN H  77;VAL H  79","None","0.85A","3qxtA-4kvnH:19.6","3qxtA-4kvnH:42.93"],["3QXT_A_MTXA2000_1","4lhj","Vicugna pacos","CAMELID ANTIBODY","PF07686(V-set);PF07705(CARDB)",5,"SER B  27;ARG B 102;MET B  34;VAL B  78;ALA B  97","None","0.97A","3qxtA-4lhjB:18.1","3qxtA-4lhjB:68.29"],["3QXT_A_MTXA2000_1","4lhq","Vicugna pacos","CAMELID NANOBODY","PF07686(V-set)",5,"ALA B  24;SER B  28;MET B  34;ARG B  72;VAL B  79","None","0.91A","3qxtA-4lhqB:21.6","3qxtA-4lhqB:64.06"],["3QXT_A_MTXA2000_1","4nc1","Lama glama","A20.1 VHH","PF07686(V-set)",7,"VAL C   9;ALA C  31;MET C  41;ARG C  79;ASN C  84;VAL C  86;ALA C 105","None","1.01A","3qxtA-4nc1C:21.9","3qxtA-4nc1C:70.99"],["3QXT_A_MTXA2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  71;ASN B  76;ALA B  97","None","0.95A","3qxtA-4nc2B:23.1","3qxtA-4nc2B:71.77"],["3QXT_A_MTXA2000_1","4orz","Lama glama","SINGLE DOMAIN ANTIBODY SDAB19","PF07686(V-set)",5,"ALA C  26;MET C  36;ARG C  73;ASN C  78;VAL C  80","None","0.96A","3qxtA-4orzC:20.7","3qxtA-4orzC:65.62"],["3QXT_A_MTXA2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",5,"MET G  34;ARG G  71;ASN G  76;VAL G  78;ALA G  97","None","0.76A","3qxtA-4p2cG:19.2","3qxtA-4p2cG:71.77"],["3QXT_A_MTXA2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",5,"VAL G   2;MET G  34;ARG G  71;VAL G  78;ALA G  97","None","0.68A","3qxtA-4p2cG:19.2","3qxtA-4p2cG:71.77"],["3QXT_A_MTXA2000_1","4py8","Homo sapiens","ANTIBODY 3.1 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL I   2;ALA I  24;ARG I  72;ASN I  77;VAL I  79","None","0.72A","3qxtA-4py8I:21.0","3qxtA-4py8I:65.32"],["3QXT_A_MTXA2000_1","4qo1","Lama glama","NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53","PF07686(V-set)",6,"ALA A  25;MET A  35;ARG A  73;ASN A  78;VAL A  80;ALA A  99","None","0.73A","3qxtA-4qo1A:20.8","3qxtA-4qo1A:63.49"],["3QXT_A_MTXA2000_1","4s10","Lama glama","GELSOLIN NANOBODY","PF07686(V-set)",5,"VAL A   2;ALA A  24;ASN A  77;VAL A  79;ALA A  98","None","0.70A","3qxtA-4s10A:22.1","3qxtA-4s10A:71.65"],["3QXT_A_MTXA2000_1","4s10","Lama glama","GELSOLIN NANOBODY","PF07686(V-set)",5,"VAL A   2;MET A  34;ASN A  77;VAL A  79;ALA A  98","None","1.03A","3qxtA-4s10A:22.1","3qxtA-4s10A:71.65"],["3QXT_A_MTXA2000_1","4tvs","Vicugna pacos","VHH DOMAIN BS-1","PF05609(LAP1C)",5,"ALA a  25;ARG a  73;ASN a  78;VAL a  80;ALA a  99","None","0.76A","3qxtA-4tvsa:22.8","3qxtA-4tvsa:73.64"],["3QXT_A_MTXA2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ASN B  77;VAL B  79;ALA B  98","None","0.93A","3qxtA-4w6yB:21.5","3qxtA-4w6yB:70.23"],["3QXT_A_MTXA2000_1","4x7f","Vicugna pacos","NANO-25 NANOBODY","PF07686(V-set)",5,"VAL C   2;ALA C  24;MET C  34;ASN C  76;VAL C  78","None","0.93A","3qxtA-4x7fC:18.9","3qxtA-4x7fC:63.49"],["3QXT_A_MTXA2000_1","4xt1","Vicugna pacos","NANOBODY 7","PF07686(V-set)",5,"VAL C   2;ALA C  24;MET C  34;VAL C  78;ALA C  97","None","0.91A","3qxtA-4xt1C:19.3","3qxtA-4xt1C:68.75"],["3QXT_A_MTXA2000_1","4ydk","Homo sapiens","HEAVY CHAIN OF ANTIBODY C38-VRC16.01","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78","None","1.03A","3qxtA-4ydkH:20.0","3qxtA-4ydkH:35.61"],["3QXT_A_MTXA2000_1","4yga","Vicugna pacos","VHH-1B7","PF07686(V-set)",5,"ALA B  25;ARG B  73;ASN B  78;VAL B  80;ALA B  99","None","0.66A","3qxtA-4ygaB:20.4","3qxtA-4ygaB:61.11"],["3QXT_A_MTXA2000_1","4zfo","Mus musculus","J22.9-XI FAB, HEAVY CHAIN","no annotation",5,"VAL H   2;ALA H  24;MET H  34;ARG H  72;ASN H  77","None","0.98A","3qxtA-4zfoH:18.7","3qxtA-4zfoH:37.95"],["3QXT_A_MTXA2000_1","5a2k","Mus musculus","IG LAMBDA-1 CHAIN V REGION S43","PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78","None","0.88A","3qxtA-5a2kH:19.9","3qxtA-5a2kH:29.44"],["3QXT_A_MTXA2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",5,"ALA H  24;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.64A","3qxtA-5aumH:19.7","3qxtA-5aumH:38.65"],["3QXT_A_MTXA2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",5,"VAL H   2;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.54A","3qxtA-5aumH:19.7","3qxtA-5aumH:38.65"],["3QXT_A_MTXA2000_1","5b6f","Mus musculus","ANTI-LEUKOTRIENE C4 MONOCLONAL ANTIBODY IMMUNOGLOBULIN GAMMA1 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"ALA B  43;MET B  53;ARG B  93;ASN B  98;VAL B 100","None","0.57A","3qxtA-5b6fB:19.3","3qxtA-5b6fB:36.02"],["3QXT_A_MTXA2000_1","5e1h","Vicugna pacos","F8(JOB10) VHH ANTIBODY","PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  72;VAL B  79","None","0.94A","3qxtA-5e1hB:20.6","3qxtA-5e1hB:69.53"],["3QXT_A_MTXA2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",5,"ALA A  26;ARG A  73;ASN A  78;VAL A  80;ALA A  99","None","0.95A","3qxtA-5e7fA:18.9","3qxtA-5e7fA:67.72"],["3QXT_A_MTXA2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",5,"MET A  36;ARG A  73;ASN A  78;VAL A  80;ALA A  99","None","0.63A","3qxtA-5e7fA:18.9","3qxtA-5e7fA:67.72"],["3QXT_A_MTXA2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",5,"VAL A   4;ALA A  26;ARG A  73;VAL A  80;ALA A  99","None","0.98A","3qxtA-5e7fA:18.9","3qxtA-5e7fA:67.72"],["3QXT_A_MTXA2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",5,"VAL A   4;MET A  36;ARG A  73;VAL A  80;ALA A  99","None","0.76A","3qxtA-5e7fA:18.9","3qxtA-5e7fA:67.72"],["3QXT_A_MTXA2000_1","5f1k","Lama glama","NANOBODY MU1053","PF07686(V-set)",5,"MET C  34;ARG C  72;ASN C  77;VAL C  79;ALA C  98","None","0.32A","3qxtA-5f1kC:22.3","3qxtA-5f1kC:68.25"],["3QXT_A_MTXA2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",5,"ALA A  24;MET A  34;ARG A  71;ASN A  76;ALA A  94","None","0.92A","3qxtA-5fwoA:21.7","3qxtA-5fwoA:68.42"],["3QXT_A_MTXA2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",6,"VAL A   2;ALA A  24;MET A  34;ARG A  71;VAL A  78;ALA A  94","None","0.92A","3qxtA-5fwoA:21.7","3qxtA-5fwoA:68.42"],["3QXT_A_MTXA2000_1","5gxb","Vicugna pacos","NANOBODY","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ASN B  77;VAL B  79;ALA B  98","None","0.92A","3qxtA-5gxbB:21.0","3qxtA-5gxbB:69.17"],["3QXT_A_MTXA2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",5,"VAL B   2;ALA B  24;ARG B  70;VAL B  77;ALA B  96","None","0.88A","3qxtA-5hvfB:18.7","3qxtA-5hvfB:70.16"],["3QXT_A_MTXA2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;VAL B  77;ALA B  96","None","1.03A","3qxtA-5hvfB:18.7","3qxtA-5hvfB:70.16"],["3QXT_A_MTXA2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",6,"ALA B  23;MET B  33;ARG B  71;ASN B  76;VAL B  78;ALA B  97","None","0.84A","3qxtA-5imlB:23.7","3qxtA-5imlB:76.19"],["3QXT_A_MTXA2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",7,"VAL C   3;ALA C  25;MET C  35;ARG C  72;ASN C  77;VAL C  79;ALA C  98","None","0.96A","3qxtA-5j1sC:19.6","3qxtA-5j1sC:66.17"],["3QXT_A_MTXA2000_1","5j56","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V1C7","PF07686(V-set)",6,"VAL B   2;ALA B  24;ARG B  76;ASN B  81;VAL B  83;ALA B 102","None","0.90A","3qxtA-5j56B:21.3","3qxtA-5j56B:67.94"],["3QXT_A_MTXA2000_1","5ja8","Lama glama","NANOBODY 2","PF07686(V-set)",5,"ALA B  25;ARG B  73;ASN B  78;VAL B  80;ALA B  99","None","0.56A","3qxtA-5ja8B:20.6","3qxtA-5ja8B:70.97"],["3QXT_A_MTXA2000_1","5ja9","Lama glama","NANOBODY 6","PF07686(V-set)",5,"ALA A  25;MET A  35;ARG A  73;ASN A  78;ALA A  99","None","1.01A","3qxtA-5ja9A:20.4","3qxtA-5ja9A:70.97"],["3QXT_A_MTXA2000_1","5jqh","Lama glama","NANOBODY60, NB60","no annotation",5,"VAL D   2;MET D  34;ARG D  71;VAL D  78;ALA D  97","None","0.97A","3qxtA-5jqhD:19.5","3qxtA-5jqhD:70.97"],["3QXT_A_MTXA2000_1","5kel","Homo sapiens","C2G4 VARIABLE FAB DOMAIN HEAVY CHAIN","PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78","None","1.01A","3qxtA-5kelH:17.3","3qxtA-5kelH:51.91"],["3QXT_A_MTXA2000_1","5lhq","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB7","PF07686(V-set)",5,"ALA B  24;ARG B  72;ASN B  77;VAL B  79;ALA B  98","None","0.54A","3qxtA-5lhqB:21.8","3qxtA-5lhqB:65.41"],["3QXT_A_MTXA2000_1","5lhq","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB7","PF07686(V-set)",5,"VAL B   2;ARG B  72;ASN B  77;VAL B  79;ALA B  98","None","0.66A","3qxtA-5lhqB:21.8","3qxtA-5lhqB:65.41"],["3QXT_A_MTXA2000_1","5lhr","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB22","PF07686(V-set)",5,"MET B  34;ARG B  72;ASN B  77;VAL B  79;ALA B  98","None","0.87A","3qxtA-5lhrB:19.9","3qxtA-5lhrB:76.80"],["3QXT_A_MTXA2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"ALA A  24;MET A  34;ARG A  71;ASN A  76;VAL A  78;ALA A  94","None","0.95A","3qxtA-5lmjA:20.3","3qxtA-5lmjA:74.02"],["3QXT_A_MTXA2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"VAL A   2;ALA A  24;ARG A  71;ASN A  76;VAL A  78;ALA A  94","None","0.89A","3qxtA-5lmjA:20.3","3qxtA-5lmjA:74.02"],["3QXT_A_MTXA2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",6,"ALA C  27;MET C  37;ARG C  75;ASN C  80;VAL C  82;ALA C 101","None","0.57A","3qxtA-5lwfC:21.3","3qxtA-5lwfC:69.60"],["3QXT_A_MTXA2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",6,"VAL C   5;MET C  37;ARG C  75;ASN C  80;VAL C  82;ALA C 101","None","0.71A","3qxtA-5lwfC:21.3","3qxtA-5lwfC:69.60"],["3QXT_A_MTXA2000_1","5mwn","Lama glama","LLAMA NANOBODY RAISED AGAINST TSSK, NBK27","PF07686(V-set)",5,"VAL N   2;ALA N  24;ARG N  71;VAL N  78;ALA N  97","None","0.91A","3qxtA-5mwnN:18.4","3qxtA-5mwnN:66.67"],["3QXT_A_MTXA2000_1","5mwn","Lama glama","LLAMA NANOBODY RAISED AGAINST TSSK, NBK27","PF07686(V-set)",5,"VAL N   2;ALA N  24;MET N  34;VAL N  78;ALA N  97","None","0.94A","3qxtA-5mwnN:18.4","3qxtA-5mwnN:66.67"],["3QXT_A_MTXA2000_1","5o05","Vicugna pacos","NANOBODY (VHH) NANO-42","PF07686(V-set)",5,"VAL C   2;ALA C  24;SER C  29;ASN C  76;VAL C  78","None","0.82A","3qxtA-5o05C:17.3","3qxtA-5o05C:66.40"],["3QXT_A_MTXA2000_1","5o8f","Lama glama","NANOBODY NB25","no annotation",5,"MET L  34;ARG L  72;ASN L  77;VAL L  79;ALA L  98","None","0.91A","3qxtA-5o8fL:21.5","3qxtA-5o8fL:69.23"],["3QXT_A_MTXA2000_1","5ovw","Lama glama","NANOBODY","no annotation",5,"ALA G  46;ARG G  94;ASN G  99;VAL G 101;ALA G 120","None","0.48A","3qxtA-5ovwG:21.6","3qxtA-5ovwG:60.28"],["3QXT_A_MTXA2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",5,"ALA p  24;MET p  34;ARG p  72;ASN p  77;ALA p  98","None","1.01A","3qxtA-5uk4p:21.7","3qxtA-5uk4p:70.63"],["3QXT_A_MTXA2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",5,"MET p  34;ARG p  72;ASN p  77;VAL p  79;ALA p  98","None","0.75A","3qxtA-5uk4p:21.7","3qxtA-5uk4p:70.63"],["3QXT_A_MTXA2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",5,"VAL p   2;MET p  34;ARG p  72;VAL p  79;ALA p  98","None","0.80A","3qxtA-5uk4p:21.7","3qxtA-5uk4p:70.63"],["3QXT_A_MTXA2000_1","5ukb","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",6,"ALA d  24;ARG d  30;ARG d  72;ASN d  77;VAL d  79;ALA d  98","None","1.05A","3qxtA-5ukbd:22.4","3qxtA-5ukbd:72.58"],["3QXT_A_MTXA2000_1","5vaq","Lama glama","NB914","no annotation",6,"ALA B  24;SER B  30;ARG B  72;ASN B  77;VAL B  79;ALA B  98","None","1.05A","3qxtA-5vaqB:22.9","3qxtA-5vaqB:76.25"],["3QXT_A_MTXA2000_1","5vgj","Homo sapiens","VRC38.01 FAB HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",6,"VAL H   2;ALA H  24;MET H  34;ARG H  71;ASN H  76;VAL H  78","None","0.64A","3qxtA-5vgjH:19.3","3qxtA-5vgjH:37.93"],["3QXT_A_MTXA2000_1","5vnw","synthetic construct","NB.B201","no annotation",5,"VAL C   2;ALA C  24;MET C  34;ASN C  76;VAL C  78","None","0.94A","3qxtA-5vnwC:21.0","3qxtA-5vnwC:75.31"],["3QXT_A_MTXA2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",5,"MET B  34;ARG B  72;ASN B  77;VAL B  79;ALA B  98","None","0.76A","3qxtA-5vxjB:19.3","3qxtA-5vxjB:63.85"],["3QXT_A_MTXA2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",5,"VAL B   2;MET B  34;ARG B  72;VAL B  79;ALA B  98","None","0.71A","3qxtA-5vxjB:19.3","3qxtA-5vxjB:63.85"],["3QXT_A_MTXA2000_1","5vxk","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-H2","no annotation",5,"ALA B  24;ARG B  72;ASN B  77;VAL B  79;ALA B  98","None","0.45A","3qxtA-5vxkB:21.5","3qxtA-5vxkB:67.16"],["3QXT_A_MTXA2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",5,"ALA B  24;MET B  34;ARG B  73;VAL B  80;ALA B  99","None","0.68A","3qxtA-5vxlB:20.4","3qxtA-5vxlB:64.84"],["3QXT_A_MTXA2000_1","5wb1","Human betaherpesvirus 5;Lama glama","ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN","no annotation",5,"VAL A1002;ALA A1024;MET A1034;VAL A1078;ALA A1097","None","0.96A","3qxtA-5wb1A:18.3","3qxtA-5wb1A:14.29"],["3QXT_A_MTXA2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"VAL A   2;ALA A  24;MET A  34;ASN A  77;VAL A  79;ALA A  98","None","0.75A","3qxtA-6dbeA:20.7","3qxtA-6dbeA:undetectable"],["3QXT_A_MTXA2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"ALA C  24;MET C  34;ARG C  72;VAL C  79;ALA C  98","None","0.65A","3qxtA-6ehgC:22.2","3qxtA-6ehgC:74.07"],["3QXT_A_MTXA2000_1","6ehg","Lama glama","HC3NB1","no annotation",5,"VAL C   2;ALA C  24;MET C  34;ARG C  72;VAL C  79","None","0.89A","3qxtA-6ehgC:22.2","3qxtA-6ehgC:74.07"],["3QXT_A_MTXA2000_1","6gzp","Lama glama","NANOBODY","no annotation",5,"ALA A  24;MET A  34;ARG A  71;ASN A  76;ALA A  94","None","0.88A","3qxtA-6gzpA:21.8","3qxtA-6gzpA:undetectable"],["3QXT_A_MTXA2000_1","6gzp","Lama glama","NANOBODY","no annotation",5,"VAL A   2;ALA A  24;MET A  34;ARG A  71;ALA A  94","None","0.83A","3qxtA-6gzpA:21.8","3qxtA-6gzpA:undetectable"]]